Stemedica CEO and leadership

Dr. Maynard Howe, as Stemedica Co-Founder and former Chief Executive Officer, brings a richly diverse background to the Company. Along with his brother, Roger, he had previously launched five successful ventures in the medical device, software, testing and measurement, quality and consulting fields. As Founder, Co-Chairman and CEO of Reliant Technologies, he led a team of scientists, engineers and physicians in developing, testing and launching the revolutionary medical laser for skin surgery known as Fraxel, an award winning medical laser technology that has resulted in defining a new category of science called fractional photothermolysis. This new science involves the role of lasers and the patient’s own stem cells in wound healing and derm/plastic surgery. The Fraxel laser, in conjunction with autologous and allogeneic stem cells, is currently being used in new clinical studies to treat scars, burn scars and diabetic ulcers. During his tenure at Reliant Technologies, the company achieved a strong intellectual property position with over 20 patents issued and 40 pending applications. In addition, Reliant had secured 13 FDA clearances, making it one of the premier market leaders with distribution in over 15 countries.

While at Reliant, Dr. Howe also led the team responsible for securing funding from individual and institutional investors including: Three Arch Partners, Pinnacle Venture Partners, Meritech Capital Partners, Delphi Ventures and Comerica Bank. Within two months of filing its S1, Reliant was sold to Solta Medical, Inc., a publicly held company (SLTM) that has and continues to pioneer and define the aesthetic industry with its innovative technology.

Prior to Reliant, Dr. Howe helped more than fifty Fortune 500 companies coordinate their company-wide quality and customer relationship initiatives. As a senior executive and co-founder of a leading customer and market research company, he was responsible for conducting extensive marketing and branding campaigns, market assessments and trend research in both business-to-business and business-to-consumer environments. Maynard is also co-founder and previous Chairman of BioPharma Scientific, LLC, specializing in the integration of pharmaceutical nanotechnology into the field of nutraceuticals.

He has experience in setting up distribution and managing sales channels throughout North America, Europe and parts of Asia for several of the companies he has co-founded.

Maynard holds a Bachelor of Science Degree, Master of Science Degree and a Doctorate in Psychology. His ability to recruit world leaders and industry experts and create a culture of innovation and teamwork has contributed to the successes achieved in the businesses he has co-founded and those in which he has provided services as a board member and consultant.

Dr. Howe is the author and co-author of numerous articles and top selling business books. He is a nationally and internationally recognized speaker and lecturer. His benchmark book on quality, “Quality on Trial, Bringing Customer Relationships into Focus“, is in its second edition and has been published in several languages. His current book, which he is a co-author, “Miracle of Stem Cells: How Adult Stem Cells are Transforming Medicine“, is in its second printing and in the process of being translated into several languages. Other books include a five part implementation manual series, “Business to Business Marketing Management System“, published by McGraw-Hill.

He is a diplomate of the American College of Forensic Examiners and an active Board Member of the USO. Previously he was a Board Member and Chairman of the Advanced Development Committee for Alliant International University. Dr. Howe continues to Chair Doctoral Dissertations in Clinical Psychology and as well as in related Behavioral Science Fields.

Dr. Kharazi is a physician by training. He finished Medical School in 1978 in Kiev, Ukraine, where he earned his medical degree in internal medicine and pathology. From 1978 to 1981, he was a post-doctoral fellow at the Kiev Institute of Gerontology. Dr. Kharazi received extensive training in cell biology and immunology, including tissue culture and subsequently earned his PhD in immunology. He studied age-related pathological changes of the immune system in mice and humans and his research interests included the possibility of restoring immunity in aged mice using stem cells from young adult mice. Dr. Kharazi was one of the first to discover the inhibitory effects of old thymus in mice and later published on this subject.

In 1989 Alex was invited to work as a research fellow in the department of Pathology at the Tokyo Metropolitan Institute of Gerontology in Japan. There, he studied early progenitors for adult thymic epithelial cells and successfully established adult thymic epithelial cell lines. He received extensive training in immuno-cytology and flow cytometry.

In 1991 Dr. Kharazi was invited to UCLA to serve as Chief Pathologist of an EPA-controlled study on the effects of magnetic fields on the incidence of lymphoma in mice. While at UCLA, he received extensive training in U.S. Good Laboratory Practices and regulatory affairs. The results of the study were reported to the United States Congress. From 1998 through 2006, Dr. Kharazi served as Chief Scientist of the Immunotherapy laboratory at St. Vincent Medical Center in Los Angeles, California. There, his research interests focused on cancer treatment using tumor vaccines, which were designed and manufactured to activate a patient’s own immune system. He successfully designed, prepared, and patented a breast cancer vaccine using genetic engineering. He also conducted scientific work on the role that dendritic cells play in the generation of anti-tumor immune response. Dr. Kharazi has hands-on experience in conducting FDA approved clinical trials. In 2006, Dr. Kharazi was invited to head stem cell research and manufacturing at Stemedica Cell Technologies in San Diego, where he established product development and GMP compliant manufacturing of human mesenchymal and neural stem cells, which allowed Stemedica to conduct phase I/II FDA approved trials in several medical applications.

Dr. Kharazi has published over 30 research articles in scientific journals and has contributed to several chapters in scholarly books. He has presented his data at numerous national and international scientific meetings. He is an active member of many distinguished societies such as The American Association for Cancer Research. In addition, he served as a consultant to several research companies and has also been a faculty member at the University of Southern California in Los Angeles. Dr. Kharazi is a named inventor of 8 US patents and various foreign patents. He is an author of numerous publications and an invited speaker/chairman on a number of stem cell meetings.

Craig Carlson is a Chief Financial Officer at Stemedica Cell Technologies and is based in San Diego, California.

Dr. Maynard Howe, as Stemedica Co-Founder and former Chief Executive Officer, brings a richly diverse background to the Company. Along with his brother, Roger, he had previously launched five successful ventures in the medical device, software, testing and measurement, quality and consulting fields. As Founder, Co-Chairman and CEO of Reliant Technologies, he led a team of scientists, engineers and physicians in developing, testing and launching the revolutionary medical laser for skin surgery known as Fraxel, an award winning medical laser technology that has resulted in defining a new category of science called fractional photothermolysis. This new science involves the role of lasers and the patient’s own stem cells in wound healing and derm/plastic surgery. The Fraxel laser, in conjunction with autologous and allogeneic stem cells, is currently being used in new clinical studies to treat scars, burn scars and diabetic ulcers. During his tenure at Reliant Technologies, the company achieved a strong intellectual property position with over 20 patents issued and 40 pending applications. In addition, Reliant had secured 13 FDA clearances, making it one of the premier market leaders with distribution in over 15 countries.

While at Reliant, Dr. Howe also led the team responsible for securing funding from individual and institutional investors including: Three Arch Partners, Pinnacle Venture Partners, Meritech Capital Partners, Delphi Ventures and Comerica Bank. Within two months of filing its S1, Reliant was sold to Solta Medical, Inc., a publicly held company (SLTM) that has and continues to pioneer and define the aesthetic industry with its innovative technology.

Prior to Reliant, Dr. Howe helped more than fifty Fortune 500 companies coordinate their company-wide quality and customer relationship initiatives. As a senior executive and co-founder of a leading customer and market research company, he was responsible for conducting extensive marketing and branding campaigns, market assessments and trend research in both business-to-business and business-to-consumer environments. Maynard is also co-founder and previous Chairman of BioPharma Scientific, LLC, specializing in the integration of pharmaceutical nanotechnology into the field of nutraceuticals.

He has experience in setting up distribution and managing sales channels throughout North America, Europe and parts of Asia for several of the companies he has co-founded.

Maynard holds a Bachelor of Science Degree, Master of Science Degree and a Doctorate in Psychology. His ability to recruit world leaders and industry experts and create a culture of innovation and teamwork has contributed to the successes achieved in the businesses he has co-founded and those in which he has provided services as a board member and consultant.

Dr. Howe is the author and co-author of numerous articles and top selling business books. He is a nationally and internationally recognized speaker and lecturer. His benchmark book on quality, “Quality on Trial, Bringing Customer Relationships into Focus“, is in its second edition and has been published in several languages. His current book, which he is a co-author, “Miracle of Stem Cells: How Adult Stem Cells are Transforming Medicine“, is in its second printing and in the process of being translated into several languages. Other books include a five part implementation manual series, “Business to Business Marketing Management System“, published by McGraw-Hill.

He is a diplomate of the American College of Forensic Examiners and an active Board Member of the USO. Previously he was a Board Member and Chairman of the Advanced Development Committee for Alliant International University. Dr. Howe continues to Chair Doctoral Dissertations in Clinical Psychology and as well as in related Behavioral Science Fields.

Dr. Maynard Howe, as Stemedica Co-Founder and former Chief Executive Officer, brings a richly diverse background to the Company. Along with his brother, Roger, he had previously launched five successful ventures in the medical device, software, testing and measurement, quality and consulting fields. As Founder, Co-Chairman and CEO of Reliant Technologies, he led a team of scientists, engineers and physicians in developing, testing and launching the revolutionary medical laser for skin surgery known as Fraxel, an award winning medical laser technology that has resulted in defining a new category of science called fractional photothermolysis. This new science involves the role of lasers and the patient’s own stem cells in wound healing and derm/plastic surgery. The Fraxel laser, in conjunction with autologous and allogeneic stem cells, is currently being used in new clinical studies to treat scars, burn scars and diabetic ulcers. During his tenure at Reliant Technologies, the company achieved a strong intellectual property position with over 20 patents issued and 40 pending applications. In addition, Reliant had secured 13 FDA clearances, making it one of the premier market leaders with distribution in over 15 countries.

While at Reliant, Dr. Howe also led the team responsible for securing funding from individual and institutional investors including: Three Arch Partners, Pinnacle Venture Partners, Meritech Capital Partners, Delphi Ventures and Comerica Bank. Within two months of filing its S1, Reliant was sold to Solta Medical, Inc., a publicly held company (SLTM) that has and continues to pioneer and define the aesthetic industry with its innovative technology.

Prior to Reliant, Dr. Howe helped more than fifty Fortune 500 companies coordinate their company-wide quality and customer relationship initiatives. As a senior executive and co-founder of a leading customer and market research company, he was responsible for conducting extensive marketing and branding campaigns, market assessments and trend research in both business-to-business and business-to-consumer environments. Maynard is also co-founder and previous Chairman of BioPharma Scientific, LLC, specializing in the integration of pharmaceutical nanotechnology into the field of nutraceuticals.

He has experience in setting up distribution and managing sales channels throughout North America, Europe and parts of Asia for several of the companies he has co-founded.

Maynard holds a Bachelor of Science Degree, Master of Science Degree and a Doctorate in Psychology. His ability to recruit world leaders and industry experts and create a culture of innovation and teamwork has contributed to the successes achieved in the businesses he has co-founded and those in which he has provided services as a board member and consultant.

Dr. Howe is the author and co-author of numerous articles and top selling business books. He is a nationally and internationally recognized speaker and lecturer. His benchmark book on quality, “Quality on Trial, Bringing Customer Relationships into Focus“, is in its second edition and has been published in several languages. His current book, which he is a co-author, “Miracle of Stem Cells: How Adult Stem Cells are Transforming Medicine“, is in its second printing and in the process of being translated into several languages. Other books include a five part implementation manual series, “Business to Business Marketing Management System“, published by McGraw-Hill.

He is a diplomate of the American College of Forensic Examiners and an active Board Member of the USO. Previously he was a Board Member and Chairman of the Advanced Development Committee for Alliant International University. Dr. Howe continues to Chair Doctoral Dissertations in Clinical Psychology and as well as in related Behavioral Science Fields.